GEN

Looking Beyond NIPT, Natera Eyes Cancer, Transplant Testing Growth

Natera says it has begun making good on its priorities for 2021, which include expansions in noninvasive prenatal testing (NIPT), transplant rejection testing, minimal residual disease (MRD) cancer ...
Business Insider

Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq ...

SAN CARLOS, Calif. and SHENZHEN, China, March 11, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the ...
Nasdaq

Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...
Business Wire

Landmark SMART Study Demonstrates High Accuracy of Natera’s Panorama® NIPT for 22q11.2 Deletion Screening

When discussing the value of screening for 22q, the authors concluded that, “the PPV of cfDNA for 22q11.2DS is higher and the false positive rate is lower than that associated with other accepted ...

All eyes on Natera earnings after surprise profit last quarter

Natera Inc. reports first-quarter results after the market closes Thursday, with investors eager to see whether the genetic testing company can build on last quarter’s blockbuster surprise or return ...
Insurancenewsnet.com

Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Assessment Test

SAN CARLOS, Calif., Dec. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination ...
Nasdaq

Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights

SAN CARLOS, Calif., June 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance ...
Business Wire

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is ...
StockStory.org on MSN

Why Natera (NTRA) shares are plunging today

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company ...
Seeking Alpha

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

Natera Inc. shows robust growth with high margins, a strong genetic testing portfolio, and a recent pullback offering an attractive entry point for investors. The company's innovative tests, like ...
Zacks Investment Research on MSN

Natera (NTRA) reports Q1 loss, tops revenue estimates

Natera (NTRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago. These figures are adjusted ...